Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts 5 thereof:

##STR00001##

The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

The present application relates to nicotinamide phosphoribosyltransferase (NAMPT) inhibitor-linker conjugates of Formula (I) comprising NAMPT inhibitors linked to linker groups, to processes and intermediates for their preparation, and to compositions comprising these compounds, as well as their use, for example, in the treatment or diagnosis of diseases and conditions, including, but not limited to, cancer.

##STR00001##

The present application relates to nicotinamide phosphoribosyltransferase (NAMPT) inhibitor-linker conjugates of Formula (I) comprising NAMPT inhibitors linked to linker groups, to processes and intermediates for their preparation, and to compositions comprising these compounds, as well as their use, for example, in the treatment or diagnosis of diseases and conditions, including, but not limited to, cancer.

##STR00001##

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

The present invention provides a palladium(II) complex of formula (1). ##STR00001## R.sub.12, m, and X are described in the specification. The invention also provides a process for the preparation of the complex, and its use in carbon-carbon and carbon-heteroatom coupling reactions.